Eugenio E. Müller

Eugenio E. Müller

Auto-generated profile, based on publicly available information

Eugenio E. Müller

Department of Pharmacology, Chemotherapy and Toxicology, University of Milan, 20129 Milan, Italy

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2010 in European Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
CBCarla Bizzarri
Carla Bizzarri
ARAntonello Emilio Rigamonti
Antonello Emilio Rigamonti
ALAntonella Luce
Antonella Luce
MCMarco Cappa
Marco Cappa
SCSilvano G Cella
Silvano G Cella
ASAlessandro Salvatoni
Alessandro Salvatoni
Background and aims: Ghrelin is an orexigenic 28-amino acid peptide produced by the stomach. Circulating ghrelin levels rise shortly before and fall shortly after every meal. Peptide YY (PYY), an anorexigenic 36-amino acid peptide, is secreted primarily from the intestinal mucosa of the ileum and large intestine. Plasma PYY levels begin to rise within 15 min after starting to eat and plateau within ∼90 min, remaining elevated for up to 6 h. Recently, some studies have tried to evaluate the potential role of ghrelin and PYY in the hyperphagia of patients with Prader–Willi syndrome (PWS). While hyperghrelinemia is well characterized in PWS, conflicting results have been reported for PYY. The aim of the study was to investigate ghrelin and PYY responses to a standard liquid high-fat meal in children with PWS.Patients and methods: Circulating levels of total ghrelin and PYY levels were assayed by RIA after overnight fasting and 45, 60, 90, and 180 min following a standard meal (Ensure 6 ml/kg) in 16 patients with PWS (11 boys and five girls, aged 4.6–10.7 years, including ten receiving 0.02 mg/kg per day rhGH for 2–18 months; body mass index (BMI) z-score: 0.6±0.2 and 1.6±0.5 for children treated or not treated with rhGH respectively), ten obese (eight boys and two girls, aged 9.2–15.6 years; BMI z-score: 2.4±0.2, i.e. BMI >97th centile for chronological age and sex) subjects, and 16 normal-weight controls (five boys and 11 girls, aged 5.8–17.3 years; BMI z-score: 0.6±0.2).Results: PWS children showed higher fasting levels of ghrelin than obese and lean controls. Postprandial ghrelin drop was more pronounced in PWS than in the other study groups. No significant difference on fasting levels of PYY was found among groups. PWS showed a higher postprandial PYY rise than obese and lean controls. PWS patients treated and not treated with GH showed similar fasting and postprandial levels of ghrelin and PYY. Fasting PYY levels correlated negatively (P<0.05; r=−0.68) with those of ghrelin only in PWS. Conclusions: The results of this study confirm fasting hyperghrelinemia in PWS. Since in PWS adults an impaired postprandial suppression of plasma ghrelin was previously reported to be associated with a blunted postprandial PYY response, the finding of a meal-induced decrease and increase in ghrelin and PYY levels respectively in PWS children would imply that the regulation of appetite/satiety of these peptides is operative during childhood, and it progressively deteriorates and vanishes in adulthood when hyperphagia and obesity worsen.

1 August 1994 in Pediatric Research
Verified
Journal Article
Closed access
PDF file
VLVittorio Locatelli
Vittorio Locatelli
RGRoberta Grilli
Roberta Grilli
ATAntonio Torsello
Antonio Torsello
SCSilvano G Cella
Silvano G Cella
WWWilliam B Wehrenberg
William B Wehrenberg
EMEugenio E Müller
Eugenio E Müller

1 September 2002 in Neurobiology of Aging
Verified
Journal Article
Closed access
EME Muller
E Muller
ARAntonello Emilio Rigamonti
Antonello Emilio Rigamonti
VCV Colonna
V Colonna
VLV Locatelli
V Locatelli
FBF Berti
F Berti
SCS Cella
S Cella

9 February 1989 in New England Journal of Medicine
Verified
Journal Article
Closed access
CPCarlo Pintor
Carlo Pintor
SLSandro Loche
Sandro Loche
SCSilvano G. Cella
Silvano G. Cella
EMEugenio E. Müller
Eugenio E. Müller
GBGerhard Baumann
Gerhard Baumann
THE regulation of somatic growth is complex and requires a number of hormones, including growth hormone, somatomedin C (insulin-like growth factor I), thyroid hormones, insulin, and sex steroids. A new development in the area of human growth hormone is the discovery of circulating growth hormone–binding proteins,1 2 3 one of which appears to be a fragment of the growth hormone receptor.4 , 5 The precise role of the binding proteins in the regulation of growth is unknown, but they may be important, directly or indirectly, in growth, since the principal binding protein is absent in patients with Laron dwarfism6 , 7 and significantly decreased in African . . .

1 September 1994 in Pediatric Research
Verified
Journal Article
Closed access
PDF file
SCSilvano G Cella
Silvano G Cella
VCVito De Gennaro Colonna
Vito De Gennaro Colonna
VLVittorio Locatelli
Vittorio Locatelli
GBGilberto E Bestetti
Gilberto E Bestetti
GRGian Luigi Rossi
Gian Luigi Rossi
EMEugenio E Müller
Eugenio E Müller

1 May 2009 in European Journal of Endocrinology
Verified
Journal Article
Closed access
LLLuigi Di Luigi
Luigi Di Luigi
ARAntonello Emilio Rigamonti
Antonello Emilio Rigamonti
FAFiorenza Agosti
Fiorenza Agosti
MMMonica Mencarelli
Monica Mencarelli
Paolo SgròPaolo Sgrò
Paolo Sgrò
Alessandro SartorioAlessandro Sartorio
Alessandro Sartorio
ObjectiveTo detect exogenous recombinant human GH (rhGH) abuse in female athletes.DesignGH-dependent markers were assayed in serum of 100 female athletes (control group) and in a subgroup of nine female subjects treated with rhGH (0.09 IU/kg body weight, 6 days/week for 3 weeks).MethodsCut-off values (mean+2 s.d.) for IGF1, N-terminal propeptide of type III procollagen (PIIINP) and C-terminal telopeptide of type I collagen (ICTP) were calculated and arbitrary scores (1.5 or 2.0) were assigned to abnormal markers. By using the sum of individual marker scores, positive (≥3) or negative (ResultsNone of the control group obtained a positive score (≥3). Abnormal IGF1, PIIINP and ICTP levels were found in 61.4, 54.5 and 11.4% samples of the treated group. Overall, positive cases were present in 43.2% blood samples drawn in subjects treated with rhGH and in 26% of samples after rhGH withdrawal. The sensitivity of the detection approach was 66.6% at the end of 3-week rhGH treatment and 11.1% at the 15th day of rhGH withdrawal, while the specificity was 100%.ConclusionDetection test for rhGH administration appears less sensitive in female (66.6%) than in male athletes (previous observation, 100% after 3 weeks of comparable rhGH dose), but shows a similar specificity (98.5–100%). Since athletes supposedly use very high doses and long-term administration of rhGH for doping purposes, it is foreseen that the here-in detection test would in future increase its strength.